Application of TACE combined with molecular targeted therapy and immunotherapy in BCLC B/C hepatocellular carcinoma
10.3760/cma.j.cn371439-20220520-00107
- VernacularTitle:TACE联合靶向、免疫治疗在BCLC B/C期肝细胞癌中的应用
- Author:
Jia SONG
1
;
Qinyong HU
Author Information
1. 武汉大学人民医院肿瘤中心，武汉 430060
- Keywords:
Carcinoma, hepatocellular;
Chemoembolization, therapeutic;
Molecular targeted therapy;
Immunotherapy;
Combined modality therapy
- From:
Journal of International Oncology
2022;49(9):550-554
- CountryChina
- Language:Chinese
-
Abstract:
Transcatheter arterial chemoembolization (TACE) is the standard treatment for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) . However, TACE has some limitations, TACE combined with systemic therapy may be more beneficial to patients with BCLC stage B/C HCC. To explore the efficacy and safety of TACE combined with molecular targeted therapy, immunotherapy and molecular targeted therapy + immunotherapy in the treatment of B/C stage HCC of BCLC will provide new ideas for the clinical treatment of HCC.
